AZ may cut supplies to boost returns

That Crestor patent challenge is coming home to roost. AstraZeneca hit a new 52-week low today as analysts publicly worried about possible generic competition for the cholesterol drug, which recently won a new indication for treatment of hardening of the arteries. "The key issue...is whether Crestor's prescriptions can accelerate on the back of the new atherosclerosis label," a Bear Stearns analyst wrote.

It's just the latest beating from analysts that AZ has taken in recent days. Another issue that has analyst tongues wagging: Inventory. The company may cut back its inventory to shore up returns; though drug makers like to keep 180 days' worth of meds on hand, a Citigroup analyst predicts AstraZeneca will reduce that margin to 90 days. If so, other Big Pharma companies may follow suit. Such a move would free up cash but the risk of shortages, which, of course, could be a PR disaster.

- learn about AZ's stock troubles from CNN Money
- read about the company's inventory decision

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.